Denileukin Diftitox Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 300 mcg
Reference Brands: Lymphir (USA/EU), Ontak (USA/EU)
Category: Oncology Cancer Care
Denileukin diftitox is a recombinant fusion protein combining human interleukin‑2 with fragments of diphtheria toxin. It selectively binds to IL‑2 receptors on malignant T-cells and delivers the toxin to kill these cells. It is used to treat adults with relapsed or refractory Cutaneous T‑cell Lymphoma (CTCL) and requires careful monitoring due to potential serious side effects such as infusion reactions, capillary leak syndrome, and liver toxicity. Denileukin Diftitox is available in Injection and strengths such as 300 mcg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Denileukin Diftitox is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Denileukin Diftitox can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Denileukin diftitox is used to treat adults with persistent or recurrent cutaneous T‑cell lymphoma (CTCL), especially in cases that have relapsed or not responded to at least one prior systemic therapy.
It is a recombinant fusion protein combining human interleukin‑2 (IL‑2) with fragments A and B of diphtheria toxin.
The trade names are Ontak and Lymphir.
The currently marketed version, Lymphir, is manufactured by Citius Pharmaceuticals, Inc.
The generic name is denileukin diftitox.
Brand names are Ontak and Lymphir.
It is produced in an E. coli expression system under Good Manufacturing Practice conditions and supplied by Citius Pharmaceuticals.
Related Products
Gemtuzumab Ozogamicin
Strength:
4.5 mg
Form: Injection
Reference Brands: Mylotarg (USA)
View Details
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
